Glaxosmithkline Pharmaceuticals Ltd

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 October 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

While the broader market showed resilience with the Sensex gaining nearly 1% on 12 Jun 2026, Glaxosmithkline Pharmaceuticals Ltd slipped to a fresh 52-week low of Rs. 2,095.95, marking a stark divergence from the general market trend.

For the second consecutive session, Glaxosmithkline Pharmaceuticals Ltd has slipped further, hitting a fresh 52-week low of Rs 2119 on 11 Jun 2026, marking a 3.03% decline over the last two days amid broader market volatility.

Glaxosmithkline Pharmaceuticals Ltd’s stock price declined to a fresh 52-week low of Rs.2136.05 on 8 June 2026, marking a significant downturn amid broader market weakness and company-specific factors. The stock has underperformed its sector and the broader market over the past year, reflecting a combination of valuation concerns and subdued growth metrics.

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 June 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

For the fifth consecutive session, Glaxosmithkline Pharmaceuticals Ltd has closed lower, slipping to a fresh 52-week low of Rs 2,166.6 on 2 Jun 2026. This decline extends the stock’s year-long underperformance, with a 33.52% drop compared to the Sensex’s 9.04% fall over the same period.

Despite a broadly positive market environment, Glaxosmithkline Pharmaceuticals Ltd has slipped to a fresh 52-week low of Rs 2,184 on 1 Jun 2026, marking a 33.4% decline over the past year and underperforming the Sensex by a wide margin.

Glaxosmithkline Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The company’s recent downgrade from a Hold to a Sell rating by MarketsMOJO reflects deteriorating price action and weakening market sentiment amid a challenging sector backdrop.

A sharp decline in Glaxosmithkline Pharmaceuticals Ltd has pushed the stock to a fresh 52-week low of Rs 2215 on 29 May 2026, marking a 31.11% drop over the past year, significantly underperforming the Sensex's 7.60% decline in the same period.

Glaxosmithkline Pharmaceuticals Ltd (NSE: 793005) has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish indicators. Despite a modest day gain of 0.78%, the stock’s broader technical parameters reveal a transition from bearish to mildly bearish trends, underscoring the need for cautious investor appraisal amid mixed signals from key momentum indicators such as MACD, RSI, and moving averages.

Glaxosmithkline Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. The company’s recent downgrade from a Hold to a Sell rating by MarketsMOJO, accompanied by a Mojo Score of 37.0, reflects growing concerns over its near-term price performance amid weakening technical signals and a subdued market environment.

Glaxosmithkline Pharmaceuticals Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a modest day decline of 0.42%, the stock’s technical indicators reveal a nuanced picture that investors must carefully analyse amid broader market trends.

Glaxosmithkline Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The company’s recent downgrade from a Hold to a Sell rating reflects deteriorating price action and weakening momentum across multiple timeframes, raising concerns for investors amid a challenging market backdrop.

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 May 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.